Keith A Zullow and Jenny J Zhang from Goodwin Procter examine upcoming US pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma looking to access the US market.
In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. For example, the US recently passed the Inflation Reduction Act,1 which requires the Secretary of Health and Human Services (HHS) to negotiate prices for certain physician-administered and retail prescription drugs covered under Medicare Parts B and D. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
There are also several pending bills that seek to lower drug costs by means other than price regulations, including:
1) deterring the delay in FDA approval of drug applications caused by sham ‘Citizen Petitions’
2) limiting the scope and number of patents asserted in litigation against proposed biosimilar entrants
3) policing anticompetitive settlements between competing drug manufacturers
4) prohibiting ‘product hopping’ and interference with generic and biosimilar substitutions
5) monitoring access to biosimilars.
European pharmaceutical companies targeting the US market should be aware of these pending bills and their potential impacts on market entry, intellectual property enforcement and payer access.
Citizen Petitions before the FDA
In the US, members of the public can request, through a Citizen Petition, that the US Food and Drug Administration (FDA) “take or refrain from taking” various administrative actions, including denying approval of generic and biosimilar drug applications.2 Submission of a Citizen Petition to the FDA obligates the regulator to address the arguments raised. Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions. Three pending bills introduced in 2021 include strategies for reducing delay caused by Citizen Petitions. Senate Bill 562 (S. 562), titled Ensuring Timely Access to Generics Act of 2021, imposes requirements related to third-party petitions concerning applications for FDA approval to market a generic or biosimilar drug. Currently, the FDA may deny a Citizen Petition as an attempt at delay only if FDA finds that the petition, 1) was submitted primarily to delay the approval of the relevant application, and 2) does not on its face raise valid scientific or regulatory issues. S. 562 would permit the FDA to deny the petition if either of these factors were satisfied.3 This same bill also requires the FDA to establish procedures for referring such petitions to the US Federal Trade Commission (FTC) as an anticompetitive business practice.
Under two other pending bills – House of Representatives Bill 2883, titled Stop Stalling Access to Affordable Medications, and Senate Bill 1425, titled Stop STALLING4 Act – it would be unfair competition to submit an “objectively baseless petition” to the FDA in an attempt to interfere with a competitor’s application to market a drug. The pending bills authorise the FTC to sue an individual or company that submits a baseless Citizen Petition for civil penalties up to $50,000 per day for each day the FDA spends reviewing the petition.5
Scope of patent litigation over proposed biosimilars House of Representatives Bill 2884, titled the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act, would limit, in certain instances, how many patents a reference-listed biologic drug product manufacturer (RPM) can assert in a lawsuit under the Biologics Price Competition and Innovation Act (BPCIA) against a company seeking to sell a biosimilar. If the biosimilar manufacturer completes specified actions under the BPCIA framework, such as sharing certain product information with the RPM, the bill would limit the number of some categories of patents that the RPM may assert in a lawsuit, such as patents filed more than four years after the reference product was approved. The limit would not apply to patents claiming certain methods for using the biologic drug and the presiding court would have discretion to adjust the limits in the interest of justice.
Anticompetitive settlements
Pending Senate Bill 1428, titled the Preserve Access to Affordable Generics and Biosimilars Act, would authorise the FTC to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. The bill would overturn current antitrust standards applied under Supreme Court case law6 by creating a presumption that an agreement has anticompetitive effects if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing or sales of the generic drug or biosimilar. Violating this bill could result in civil penalties (which could be trebled), injunctions, and forfeiture of the 180-day marketing exclusivity period for a generic drug.
‘Drug hopping’ and interference with substitution
Several related pending bills7 would prohibit so-called ‘product hopping’. Product hopping arises if, around when patents covering a reference drug expire, the reference drug manufacturer withdraws the reference drug or otherwise disadvantages generic competition in an attempt to convert the market to a modified version of the drug covered by later-expiring patents. The pending bills would authorise the FTC to enforce the product hopping prohibition by seeking disgorgement of a product hopper’s unjust enrichment in Federal Court.
Another pending bill, House of Representatives Bill 7473, titled the Generic Substitution Noninterference Act, would more directly prohibit attempts to interfere with the substitution of reference drug products by therapeutically equivalent generics or interchangeable biosimilars. Specifically, the pending bill would make it unlawful for a pharmaceutical manufacturer to direct or incentivise a healthcare provider to prevent substitution when generic or biosimilar substitutes are available, for example, by requesting that a drug be dispensed “as written” or “brand name only”.
Measuring and rating biosimilar access
Pending House of Representatives Bill 2855, titled Star Rating for Biosimilars Act, aims to more effectively identify barriers to biosimilar access by requiring HHS to implement a quality measure to capture patient use and access to biosimilars and evaluate Medicare Advantage plans based on those measures.
Conclusion
Although it is unclear which, if any, of these pending bills will be enacted before the end of the Congressional Session in January 2023, or how such pending bills may be modified before passage, the existence of these pending bills evidence the focus that the US Congress is currently placing on reducing prescription drug prices. Enactment of any of these measures could present both opportunities and challenges to European pharmaceutical manufacturers: generic and biosimilar manufacturers might find a more streamlined path to intellectual property clearance, approval, and/or payor access, while branded manufacturers may need to re-evaluate and/or modify strategies for maintaining intellectual property and regulatory based exclusivities.
21 C.F.R. § 10.25(a) (“An interested person may petition the Commissioner to issue, amend, or revoke a regulation or order, or to take or refrain from taking any other form of administrative action.”), https://www.ecfr.gov/current/title-21/chapter-I/ subchapter-A/part-10/subpart-B/section-10.25; 21 U.S.C. § 355(q), https://www. govinfo.gov/content/pkg/USCODE-2020-title21/pdf/USCODE-2020-title21-chap9- subchapV-partA-sec355.pdf; 21 C.F.R. § 10.30(e)(2), https://www.ecfr.gov/current/ title-21/chapter-I/subchapter-A/part-10/subpart-B/section-10.30.
S. 562, 117th Cong. § 2(1)(B)(i) (2021), https://www.congress.gov/bill/117thcongress/ senate-bill/562/text.
STALLING is an acronym for “Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics.”
FTC v. Actavis, 570 U.S. 136 (2013), https://www.supremecourt.gov/ opinions/12pdf/12-416_m5n0.pdf.
S. 1435 (“Affordable Prescriptions for Patients Act of 2021”), https://www.congress. gov/bill/117th-congress/senate-bill/1435/text; H.R. 2873 (“Affordable Prescriptions for Patients Through Promoting Competition Act of 2021”), https://www.congress. gov/bill/117th-congress/house-bill/2873/text; H.R. 2884 (“Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act”), https://www.congress. gov/bill/117th-congress/house-bill/2884/text; H.R. 5237 (“Reduced Costs and Continued Cures Act of 2021”), https://www.congress.gov/bill/117th-congress/ house-bill/5237/text; H.R. 5260 (“Reduced Costs and Continued Cures Act”), https://www.congress.gov/bill/117th-congress/house-bill/5260/text.
Keith A Zullow is a US Registered Patent Attorney and a partner in Goodwin’s Intellectual Property Litigation group in New York. He focuses his practice on patent counselling and patent litigation in life sciences and other technologies.
Jenny J Zhang is a US Registered Patent Attorney and a senior associate in Goodwin’s Intellectual Property Litigation group in DC. She focuses her practice on litigation over life sciences and other technologies.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.